The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents

Oncogene

Volumn 33, Issue 1, 2014, Pages 85-96

  Lin, M Z ^a   Marzec, K A ^a   Martin, J L ^a   Baxter, R C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

breast cancer; DNA damaging therapy; DNA PK; EGFR; IGFBP 3

Indexed keywords

ANTINEOPLASTIC AGENT; DNA DAMAGING AGENT; DNA DEPENDENT PROTEIN KINASE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; ETOPOSIDE; GEFITINIB; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CELL NUCLEUS; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; IMMUNOPRECIPITATION; LIGATION; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; RADIATION EXPOSURE; TRANSACTIVATION;

EID: 84891737317     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.538     Document Type: Article

References (68)

1. McPherson K, Steel CM, Dixon JM. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000; 321: 624-628.
2. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (The International Cancer Benchmarking Partnership): An analysis of populationbased cancer registry data. Lancet 2011; 377: 127-138.
3. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011; 61: 409-418.
4. Chen S, Inamdar KV, Pfeiffer P, Feldmann E, Hannah MF, Yu Y et al. Accurate in vitro end joining of a DNA double strand break with partially cohesive 30-overhangs and 30-phosphoglycolate termini. Effect of Ku on repair fidelity. J Biol Chem 2001; 276: 24323-24330.
5. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L et al. Radiationinduced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005; 280: 31182-31189. (Pubitemid 41291855)
6. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MCM, Kros JM, Carpentier AF et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009; 27: 1268-1274.
7. Reardon D, Desjardins A, Vredenburgh J, Gururangan S, Friedman A, Herndon J et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neuro-Oncol 2010; 96: 219-230.
8. Schedlich LJ, Nilsen T, John AP, Jans DA, Baxter RC. Phosphorylation of insulin-like growth factor binding protein-3 by deoxyribonucleic acid-dependent protein kinase reduces ligand binding and enhances nuclear accumulation. Endocrinology 2003; 144: 1984-1993. (Pubitemid 36543338)
9. Martin JL, Weenink SM, Baxter RC. Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells. J Biol Chem 2003; 278: 2969-2976.
10. Baxter RC. Circulating binding proteins for the insulinlike growth factors. Trends Endocrinol Metab 1993; 4: 91-96. (Pubitemid 23144186)
11. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-854. (Pubitemid 35454590)
12. Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008; 36: 160-167.
13. Xi Y, Nakajima G, Hamil T, Fodstad O, Riker A, Ju J. Association of insulin-like growth factor binding protein-3 expression with melanoma progression. Mol Cancer Ther 2006; 5: 3078-3084. (Pubitemid 46092049)
14. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1: 203-209. (Pubitemid 41039166)
15. Chuang ST, Patton KT, Schafernak KT, Papavero V, Lin F, Baxter RC et al. Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. J Urol 2008; 179: 445-449.
16. Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: Detection of higher levels in tumors with poor prognostic features. J Nat Cancer Inst 1996; 88: 601-606. (Pubitemid 26137582)
17. Yu H, Levesque MA, Khosravi MJ, Papanastasiou DA, Clark GM, Diamandis EP. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Brit J Cancer 1996; 74: 1242-1247. (Pubitemid 26360113)
18. Sheen-Chen SM, Zhang H, Huang CC, Tang RP. Insulin-like growth factor-binding protein-3 in breast cancer: Analysis with tissue microarray. Anticancer Res 2009; 29: 1131-1135.
19. Grkovic S, O'Reilly VC, Han S, Hong M, Baxter RC, Firth SM. IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments. Oncogene 2012doi:10.1038/onc.2012.264.
20. Martin JL, Lin MZ, McGowan EM, Baxter RC. Potentiation of growth factor signaling by insulin-like growth factor-binding protein-3 in breast epithelial cells requires sphingosine kinase activity. J Biol Chem 2009; 284: 25542-25552.
21. Butt AJ, Martin JL, Dickson KA, McDougall F, Firth SM, Baxter RC. Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. J Clin Endocrinol Metab 2004; 89: 1950-1956. (Pubitemid 38507956)
22. Cobb LJ, Liu B, Lee K-W, Cohen P. Phosphorylation by DNA-dependent protein kinase is critical for apoptosis induction by insulin-like growth factor binding protein-3. Cancer Res 2006; 66: 10878-10884. (Pubitemid 44876985)
23. Chen BPC, Chan DW, Kobayashi J, Burma S, Asaithamby A, Morotomi-Yano K et al. Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. J Biol Chem 2005; 280: 14709-14715. (Pubitemid 40562818)
24. Santer FR, Bacher N, Moser B, Morandell D, Ressler S, Firth SM et al. Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis. Cancer Res 2006; 66: 3024-3033.
25. Andrin C, McDonald D, Attwood KM, Rodrigue A, Ghosh S, Mirzayans R et al. A requirement for polymerized actin in DNA double-strand break repair. Nucleus 2012; 3: 384-395.
26. Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000; 275: 39174-39181. (Pubitemid 32058934)
27. Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM et al. Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res 2000; 60: 22-27. (Pubitemid 30058723)
28. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997; 386: 763.
29. Mineo C, Gill GN, Anderson RGW. Regulated migration of epidermal growth factor receptor from caveolae. J Biol Chem 1999; 274: 30636-30643.
30. Wang X-Q, Paller AS. Lipid rafts: membrane triage centers. J Invest Dermatol 2006; 126: 951-953.
31. Hanzal-Bayer MF, Hancock JF. Lipid rafts and membrane traffic. FEBS Lett 2007; 581: 2098-2104. (Pubitemid 46709907)
32. Lee KW, Liu B, Ma L, Li H, Bang P, Koeffler HP et al. Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization. J Biol Chem 2004; 279: 469-476. (Pubitemid 38044848)
33. Kenworthy AK, Petranova N, Edidin M. High-resolution FRET microscopy of cholera toxin b-subunit and GPI-anchored proteins in cell plasma membranes. Mol Biol Cell 2000; 11: 1645-1655. (Pubitemid 30307902)
34. Abulrob A, Giuseppin S, Andrade MF, McDermid A, Moreno M, Stanimirovic D. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene 2004; 23: 6967-6979. (Pubitemid 39279997)
35. Ferguson DO, Alt FW. DNA double strand break repair and chromosomal translocation: lessons from animal models. Oncogene 2001; 20: 5572-5579. (Pubitemid 32928098)
36. Smith GCM, Jackson SP. The DNA-dependent protein kinase. Genes Devel 1999; 13: 916-934. (Pubitemid 29200976)
37. van Gent DC, Hoeijmakers JHJ, Kanaar R. Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet 2001; 2: 196-206. (Pubitemid 33674018)
38. Carpenter G, Liao H-J. Trafficking of receptor tyrosine kinases to the nucleus. Exptl Cell Research 2009; 315: 1556-1566.
39. Dittmann K, Mayer C, Rodemann H. Nuclear EGFR as novel therapeutic target. Strahlenther Onkol 2010; 186: 1-6.
40. Muller C, Christodoulopoulos G, Salles B, Panasci L. DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood 1998; 92: 2213-2219. (Pubitemid 28452960)
41. Jeggo PA. Identification of genes involved in repair of DNA double-strand breaks in mammalian cells. Radiat Res 1998; 150: S80-S91. (Pubitemid 28519053)
42. Hsu SC, Miller SA, Wang Y, Hung MC. Nuclear EGFR is required for cisplatin resistance and DNA repair. Am J Transl Res 2009; 1: 249-258.
43. Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A et al. Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol Cancer Ther 2006; 5: 209-218.
44. Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006; 94: 1604-1609. (Pubitemid 43924921)
45. Arnes JB, Begin LR, Stefansson I, Brunet JS, Nielsen TO, Foulkes WD et al. Expression of epidermal growth factor receptor in relation to BRCA1 status, basallike markers and prognosis in breast cancer. J Clin Pathol 2009; 62: 139-146.
46. Putti TC, El-Rehim DMA, Rakha EA, Paish CE, Lee AHS, Pinder SE et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2004; 18: 26-35.
47. Clemmons DR, Camacho-Hü bner C, Coronado E, Osborne CK. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology 1990; 127: 2679-2686.
48. Martin JL, Baxter RC. Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway. Endocrinology 2007; 148: 2532-2541. (Pubitemid 46997047)
49. Rinaldi S, Peeters PHM, Berrino F, Dossus L, Biessy C, Olsen A et al. IGF-I, IGFBP-3 and breast cancer risk in women: the european prospective investigation into cancer and nutrition (EPIC). Endocr Relat Cancer 2006; 13: 593-605. (Pubitemid 43886679)
50. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-1353. (Pubitemid 38529873)
51. Probst-Hensch NM, Steiner JHB, Schraml P, Varga Z, Zürrer-Härdi U, Storz M et al. IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clin Cancer Res 2010; 16: 1025-1032.
52. O'Han MK, Baxter RC, Schedlich LJ. Effects of endogenous insulin-like growth factor binding protein-3 on cell cycle regulation in breast cancer cells. Growth Factors 2009; 27: 394-408.
53. Hasty P. Is NHEJ a tumor suppressor or an aging suppressor Cell Cycle 2008; 7: 1139-1145.
54. Dominguez-Brauer C, Brauer PM, Chen YJ, Pimkina J, Raychaudhuri P. Tumor suppression by ARF: gatekeeper and caretaker. Cell Cycle 2010; 9: 86-89.
55. Li ML, Greenberg RA. Links between genome integrity and BRCA1 tumor suppression. Trends Biochem Sci 2012; 37: 418-424.
56. Yarden RI, Metsuyanim S, Pickholtz I, Shabbeer S, Tellio H, Papa MZ. BRCA1-dependent Chk1 phosphorylation triggers partial chromatin disassociation of phosphorylated Chk1 and facilitates S-phase cell cycle arrest. Int J Biochem Cell Biol 2012; 44: 1761-1769.
57. McIntosh J, Dennison G, Holly JMP, Jarrett C, Frankow A, Foulstone EJ et al. IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin. J Biol Chem 2010; 285: 38788-38800.
58. Yoon JH, Ahn SG, Lee BH, Jung SH, Oh SH. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1. Biochem Pharmacol 2012; 83: 747-757.
59. Schedlich LJ, Young TF, Firth SM, Baxter RC. Insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem 1998; 273: 18347-18352. (Pubitemid 28334760)
60. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC. Nuclear import of insulin-like growth factor-binding protein-3 and-5 is mediated by the importin beta subunit. J Biol Chem 2000; 275: 23462-23470. (Pubitemid 30624626)
61. Liccardi G, Hartley JA, Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res 2011; 71: 1103-1114.
62. Dittmann K, Mayer C, Kehlbach R, Rodemann HP. Radiation-induced caveolin-1associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer 2008; 7: 69.
63. Dennison G, Holly J, McIntosh J, Winters Z, Perks C. Insulin-like growth factor binding protein 3 modulates epidermal growth factor (EGF)-induced growth of breast epithelial cells by altering EGF receptor internalization. Breast Cancer Res 2008; 10: P40.
64. Micutkova L, Hermann M, Offterdinger M, Hess MW, Matscheski A, Pircher H et al. Analysis of the cellular uptake and nuclear delivery of insulin-like growth factor binding protein-3 in human osteosarcoma cells. Int J Cancer 2012; 130: 1544-1557.
65. Paharkova-Vatchkova V, Lee K-W. Nuclear export and mitochondrial and endoplasmic reticulum localization of IGF-binding protein 3 regulate its apoptotic properties. Endocr Relat Cancer 2010; 17: 293-302.
66. Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2011; 226: 2316-2328.
67. Feldmann E, Schmiemann V, Goedecke W, Reichenberger S, Pfeiffer P. DNA double-strand break repair in cell-free extracts from Ku80-deficient cells: implications for Ku serving as an alignment factor in non-homologous DNA end joining. Nucleic Acids Res 2000; 28: 2585-2596. (Pubitemid 30420858)
68. Andrin C, Hendzel MJ. F-actin-dependent insolubility of chromatin-modifying components. J Biol Chem 2004; 279: 25017-25023. (Pubitemid 38756750)